Results 51 to 60 of about 337,805 (303)

Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence

open access: yesNature Genetics, 2021
Esophageal squamous cell carcinoma (ESCC) shows remarkable variation in incidence that is not fully explained by known lifestyle and environmental risk factors. It has been speculated that an unknown exogenous exposure(s) could be responsible.
Sarah Moody   +52 more
semanticscholar   +1 more source

RNA editing is induced by type I interferon in esophageal squamous cell carcinoma

open access: yesTumor Biology, 2017
In recent years, abnormal RNA editing has been shown to play an important role in the development of esophageal squamous cell carcinoma, as such abnormal editing is catalyzed by ADAR (adenosine deaminases acting on RNA). However, the regulatory mechanism
Jinyao Zhang   +5 more
doaj   +1 more source

High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma

open access: yesTumor Biology, 2017
Patients with esophageal squamous cell carcinoma have poor survival and high recurrence rate, thus an effective prognostic biomarker is needed. Endothelin-converting enzyme-1 is responsible for biosynthesis of endothelin-1, which promotes growth and ...
Ching-Fang Wu   +6 more
doaj   +1 more source

LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma

open access: yesCell Death and Disease, 2021
Tumor cells require high levels of cholesterol for membrane biogenesis for rapid proliferation during development. Beyond the acquired cholesterol from low-density lipoprotein (LDL) taken up from circulation, tumor cells can also biosynthesize ...
Mingyue Tao   +16 more
semanticscholar   +1 more source

The long-term impact of tumor burden in pT3N0M0 esophageal squamous cell carcinoma

open access: yesMedicine, 2019
The purpose of this study was to assess the impact of tumor burden on the survival of patients with pathologic T3N0M0 (pT3N0M0) esophageal squamous cell carcinoma (ESCC).
Tingting Li   +6 more
semanticscholar   +1 more source

Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma

open access: yesJAMA Network Open, 2020
Key Points Question Are peritumoral radiomics features extracted from pretreatment computed tomography images predictive of pathological complete response following neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma?
Yihuai Hu   +8 more
semanticscholar   +1 more source

Toll-like receptors in esophageal cancer

open access: yesFrontiers in Immunology, 2014
Esophageal squamous cell carcinoma and esophageal adenocarcinoma are cancers of high mortality. Esophageal adenocarcinoma develops through Barrett’s esophagus and columnar dysplasia, preceded by gastroesophageal reflux disease.
Joonas H Kauppila   +5 more
doaj   +1 more source

Esophageal Neuroendocrine Carcinoma With Focal Squamous Cell Carcinoma Component

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2020
This study was about a 70-year-old man with progressive dysphagia. Esophagogastroduodenoscopy showed a 1.2-cm circumferential ulcerative mass at the level of 23 cm from the upper incisors in the upper esophagus.
Min Kyun Kang, Do Kyun Kang
doaj   +1 more source

Biobanking for Esophageal Squamous Cell Carcinoma

open access: yes, 2020
Biobanking is important and fundamental for research and personalized medicine in patients with esophageal squamous cell carcinoma. The process often involves prospective collection of surgically obtained tissues (tissue banking) as well as serial blood samples (liquid biopsies) from the patients with esophageal squamous cell carcinoma.
openaire   +3 more sources

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

open access: yesNature Medicine
Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results.
J. Qin   +45 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy